Noden Pharma Notified of ANDA Filing for Tekturna®

INCLINE VILLAGE, N.V., June 5, 2017 /PRNewswire/ — PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its subsidiary, Noden Pharma DAC (Noden), received a Paragraph IV Notice Letter advising that Anchen Pharmaceuticals, Inc. (Anchen) submitted an Abbreviated New Drug Application (“ANDA”) to the United States Food and Drug Administration (FDA) seeking authorization from the FDA to manufacture and market a generic version of Tekturna ® aliskiren hemifumarate tablets, 150 mg and 300 mg, in the United States.
Read Full Text

Leave a Reply

Your email address will not be published. Required fields are marked *